Kaleido Biosciences, Inc.
KLDO
$0.002
$0.00191,900.00%
OTC PK
| 12/31/2021 | 09/30/2021 | 06/30/2021 | 03/31/2021 | 12/31/2020 | |
|---|---|---|---|---|---|
| Revenue | 13.23% | 16.80% | 393.20% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.23% | 16.80% | 393.20% | -- | -- |
| Cost of Revenue | 21.15% | -37.12% | -28.14% | -37.58% | -- |
| Gross Profit | -21.29% | 37.49% | 29.32% | 38.90% | -- |
| SG&A Expenses | -12.20% | -8.51% | 6.11% | 2.24% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -175.13% | -- | -- | -- | -- |
| Total Operating Expenses | 10.72% | 11.40% | 12.89% | -1.72% | -- |
| Operating Income | -10.69% | -11.35% | -11.68% | 3.22% | -- |
| Income Before Tax | -10.62% | -10.99% | -12.67% | 0.64% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.62% | -10.99% | -12.67% | 0.64% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.62% | -10.99% | -12.67% | 0.64% | -- |
| EBIT | -10.69% | -11.35% | -11.68% | 3.22% | -- |
| EBITDA | -10.25% | -10.68% | -11.03% | 4.03% | -- |
| EPS Basic | 11.64% | 11.68% | 10.41% | 16.72% | -- |
| Normalized Basic EPS | 11.65% | 11.01% | 9.75% | 16.15% | -- |
| EPS Diluted | 11.64% | 11.68% | 10.41% | 16.72% | -- |
| Normalized Diluted EPS | 11.65% | 11.01% | 9.75% | 16.15% | -- |
| Average Basic Shares Outstanding | 25.17% | 25.76% | 25.87% | 19.31% | -- |
| Average Diluted Shares Outstanding | 25.17% | 25.76% | 25.87% | 19.31% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |